Timing of P2Y12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI
Manuel Almendro-Delia1, Begoña Hernández-Meneses1, Gloria Padilla-Rodríguez1
1Acute Cardiovascular Care Unit, Hospital Universitario Virgen Macarena, Seville, Spain.
Insights
Pretreating ST-segment elevation myocardial infarction (STEMI) patients with P2Y12 inhibitors before angiography significantly reduces major adverse cardiac events (MACE) within 30 days. This pretreatment strategy also avoids increasing bleeding risk, offering a net clinical benefit.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- The optimal timing for administering P2Y12 inhibitors in ST-segment elevation myocardial infarction (STEMI) patients remains unclear.
- This study investigates the safety and efficacy of P2Y12 inhibitor pretreatment in STEMI patients undergoing primary percutaneous coronary intervention (PCI).
Purpose of the Study:
- To assess the impact of P2Y12 inhibitor pretreatment on major adverse cardiac events (MACE), major bleeding, and net adverse clinical events (NACE) within 30 days.
- To evaluate the association between P2Y12 inhibitor pretreatment and clinical outcomes in a regional STEMI network.
Main Methods:
- Analysis of a prospective multicenter registry including 1,624 STEMI patients.
- Pretreatment defined as P2Y12 inhibitor administration before coronary angiography.
- Propensity score analysis with doubly robust weighted estimators to adjust for confounding factors.
Main Results:
- P2Y12 inhibitor pretreatment was associated with a reduced risk of MACE (adjusted HR: 0.53) and superior net clinical benefit (adjusted HR: 0.47).
- No significant increase in major bleeding risk was observed with pretreatment (adjusted HR: 0.62).
- The benefits of pretreatment on MACE were time-dependent, becoming apparent when the interval between administration and PCI exceeded 80 minutes.
Conclusions:
- Pretreatment with P2Y12 inhibitors in STEMI patients transferred for primary PCI is associated with a time-dependent reduction in 30-day MACE.
- This strategy does not increase bleeding risk, leading to improved net clinical outcomes.
- The findings highlight the importance of timing in P2Y12 inhibitor administration for STEMI management.
Background:
The optimal timing of P2Y12 inhibitor administration in patients with ST-segment elevation myocardial infarction (STEMI) has not been completely elucidating.
Objectives:
This analysis from a prospective multicenter registry sought to assess the safety and effectiveness of P2Y12 inhibitor pretreatment in patients transferred for primary percutaneous coronary intervention (PCI) within a regional STEMI network.
Methods:
Pretreatment was defined as P2Y12 inhibitor administration before coronary angiography. Endpoints were major adverse cardiac events (MACE), major bleeding, and net adverse clinical events, a composite of MACE or major bleeding, within 30 days of index admission. Association of P2Y12 inhibitor pretreatment with outcomes was modeled using doubly robust weighted estimators based on propensity score analysis.
Results:
Of 1,624 patients included, 1,033 received P2Y12 inhibitors before angiography and 591 in the catheterization laboratory (cath lab). The non-pretreated cohort more often had history of coronary artery disease and were more likely to receive antiplatelet therapy before the index admission. After adjustment for confounding and dependent censoring, pretreatment with P2Y12 inhibitors predicted lower risk of MACE (adjusted HR: 0.53; 95% CI: 0.37-0.76), without increasing bleeding risk (adjusted HR: 0.62; 95% CI: 0.36-1.05), resulting in superior net clinical benefit (adjusted HR: 0.47; 95% CI: 0.26-0.86) compared with in-cath lab administration of P2Y12 inhibitors. There was a significant treatment-by-time interaction for MACE risk, whereby the observed benefits of pretreatment only became apparent when time between P2Y12 inhibitor administration and PCI was longer than 80 minutes.
Conclusions:
In contemporary patients with STEMI transferred for primary PCI, pretreatment with P2Y12 inhibitors was associated with a significant time-dependent reduction of 30-day MACE without increasing bleeding risk.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...